Last Price$395.5(0.3%)
Market Cap$90.7B
LTM EBITDA margin
24.8%
5Y avg
7.6%
Medical - Healthcare Plans industry
median
3.2%
Stock quality & Intrinsic value
7/10
1.5% undervalued
Elevance Health Inc. EBITDA margin
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA margin | 10.2% | 10.3% | 10.2% | 6.7% | 13.6% | 8.7% | 7.8% | 7.7% | 6.7% | 7.2% | 7.1% | 6.6% | 5.5% | 6.8% | 6.9% | 6.7% | 4.3% | 6.5% | 6.1% | 0.0% |
Overvalued or undervalued?
Check the intrinsic value for ELV
and see if it's the right time to invest.
Elevance Health Inc. (ELV) EBITDA margin comparison analysis
General
LTM EBITDA margin
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Elevance Health Inc.ELV
24.8%
3.2%
(0.0%)
3.4%
Median Peer Set
3.2%
8.7%
(11.9%)
1.1%
UnitedHealth Group IncorporatedUNH
6.0%
8.9%
(35.7%)
3.6%
Molina Healthcare, Inc.MOH
4.7%
19.3%
9.2%
2.9%
Cigna CorporationCI
4.6%
8.4%
(18.9%)
2.6%
CVS Health CorporationCVS
3.7%
4.2%
(43.6%)
1.2%
Centene CorporationCNC
3.4%
5.9%
27.4%
2.0%
Humana Inc.HUM
2.9%
10.7%
(50.1%)
1.0%
Oscar Health, Inc.OSCR
1.0%
56.5%
N/A
0.3%
Alignment Healthcare, Inc.ALHC
(2.9%)
27.2%
(4.8%)
(8.1%)
Clover Health Investments, Corp.CLOV
(3.2%)
(41.5%)
(31.3%)
(10.5%)
Bright Health Group, Inc.BHG
(22.6%)
(51.9%)
86.2%
(103.4%)
ELV key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 45,150.8 116.9% | 57,009.2 26.3% | 61,394.0 7.7% | 62,459.0 1.7% | 61,644.3 (1.3%) | 58,841.2 (4.5%) | 60,804.0 3.3% | 61,535.0 1.2% | 71,122.4 15.6% | 73,923.1 3.9% | 79,239.9 7.2% | 84,978.4 7.2% | 90,039.4 6.0% | 92,105.0 2.3% | 104,213.0 13.1% | 121,867.0 16.9% | 138,639.0 13.8% | 156,595.0 13.0% | 171,340.0 9.4% | 176,810.0 3.2% |
| Cost of Goods Sold (COGS) | 33,507.9 | 42,520.0 | 46,436.3 | 48,210.9 | 46,990.1 | 44,926.9 | 47,647.5 | 48,213.6 | 56,237.1 | 56,854.9 | 61,116.9 | 66,834.4 | 72,236.2 | 71,895.0 | 81,786.0 | 88,045.0 | 102,645.0 | 116,642.0 | 124,330.0 | 19,750.0 |
% margin | 11,642.9 25.8% | 14,489.2 25.4% | 14,957.7 24.4% | 14,248.1 22.8% | 14,654.2 23.8% | 13,914.3 23.6% | 13,156.5 21.6% | 13,321.4 21.6% | 14,885.3 20.9% | 17,068.2 23.1% | 18,123.0 22.9% | 18,144.0 21.4% | 17,803.2 19.8% | 20,210.0 21.9% | 22,427.0 21.5% | 33,822.0 27.8% | 35,994.0 26.0% | 39,953.0 25.5% | 47,010.0 27.4% | 157,060.0 88.8% |
| Operating Expenses | 7,511.1 | 9,126.2 | 9,003.0 | 9,287.5 | 9,711.6 | 9,081.1 | 8,675.0 | 8,913.5 | 10,198.2 | 11,969.3 | 12,764.9 | 12,724.9 | 12,818.0 | 14,373.0 | 15,694.0 | 26,111.0 | 27,048.0 | 31,502.0 | 38,265.0 | 20,025.0 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Selling, General & Administrative Expenses (SG&A) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
% margin | 4,131.8 9.2% | 5,363.0 9.4% | 5,954.7 9.7% | 4,960.6 7.9% | 4,942.6 8.0% | 4,833.2 8.2% | 4,481.5 7.4% | 4,407.9 7.2% | 4,687.1 6.6% | 5,098.9 6.9% | 5,358.1 6.8% | 5,419.1 6.4% | 4,985.2 5.5% | 5,837.0 6.3% | 6,733.0 6.5% | 7,711.0 6.3% | 8,946.0 6.5% | 8,451.0 5.4% | 8,745.0 5.1% | 137,236.0 77.6% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest Expense | 226.7 | 392.4 | 437.1 | 488.9 | 447.6 | 418.9 | 430.3 | 511.8 | 602.7 | 600.7 | 653.0 | 723.0 | 739.0 | 753.0 | 746.0 | 784.0 | 798.0 | 851.0 | 1,030.0 | 1,185.0 |
| Pre-tax Income | 3,890.3 | 4,914.4 | 5,257.9 | 3,122.4 | 7,403.0 | 4,353.8 | 3,957.9 | 3,858.3 | 3,840.2 | 4,368.1 | 4,631.0 | 4,555.4 | 3,963.8 | 5,068.0 | 5,985.0 | 6,238.0 | 7,925.0 | 7,600.0 | 7,715.0 | 7,904.0 |
% effective tax rate | 1,426.5 36.7% | 1,819.5 37.0% | 1,912.5 36.4% | 631.7 20.2% | 2,657.1 35.9% | 1,466.7 33.7% | 1,311.2 33.1% | 1,207.3 31.3% | 1,205.9 31.4% | 1,808.0 41.4% | 2,071.0 44.7% | 2,085.6 45.8% | 121.0 3.1% | 1,318.0 26.0% | 1,178.0 19.7% | 1,666.0 26.7% | 1,830.0 23.1% | 1,712.0 22.5% | 1,724.0 22.3% | 1,933.0 24.5% |
% margin | 2,463.8 5.5% | 3,094.9 5.4% | 3,345.4 5.4% | 2,490.7 4.0% | 4,745.9 7.7% | 2,887.1 4.9% | 2,646.7 4.4% | 2,655.5 4.3% | 2,654.2 3.7% | 2,569.7 3.5% | 2,560.0 3.2% | 2,469.8 2.9% | 3,842.8 4.3% | 3,750.0 4.1% | 4,807.0 4.6% | 4,572.0 3.8% | 6,104.0 4.4% | 5,894.0 3.8% | 5,987.0 3.5% | 5,980.0 3.4% |
| EPS | 4.03 | 4.93 | 5.64 | 4.79 | 9.96 | 7.03 | 7.35 | 8.26 | 8.89 | 9.31 | 9.73 | 9.39 | 14.70 | 14.53 | 18.81 | 18.23 | 25.04 | 24.56 | 25.69 | 25.68 |
| Diluted EPS | 3.94 | 4.82 | 5.56 | 4.76 | 9.88 | 6.94 | 7.25 | 8.18 | 8.74 | 8.95 | 9.38 | 9.21 | 14.35 | 14.19 | 18.47 | 17.98 | 24.73 | 24.28 | 25.22 | 25.68 |
% margin | 4,584.5 10.2% | 5,874.6 10.3% | 6,252.6 10.2% | 4,174.8 6.7% | 8,408.0 13.6% | 5,117.5 8.7% | 4,723.3 7.8% | 4,710.2 7.7% | 4,796.1 6.7% | 5,296.2 7.2% | 5,619.9 7.1% | 5,574.7 6.6% | 4,981.9 5.5% | 6,303.0 6.8% | 7,216.0 6.9% | 8,176.0 6.7% | 6,004.0 4.3% | 10,126.0 6.5% | 10,490.0 6.1% | 0.0 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Elevance Health Inc.'s EBITDA margin?
As of today, Microsoft Corp's last 12-month EBITDA margin is 24.8%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual EBITDA margin for Elevance Health Inc. have been 7.8% over the past three years, and 8.0% over the past five years.
2) Is Elevance Health Inc.'s EBITDA margin Good?
As of today, Elevance Health Inc.'s EBITDA margin is 24.8%, which is higher than industry median of 3.2%. It indicates that Elevance Health Inc.'s EBITDA margin is Good.